To evaluate visual outcomes and patient satisfactory after PanOptix implantation in hyperopic cataract patients

Patients with axial length ≤22.5mm will be recruited. The subjects will undergo bilateral uneventful phacoemulsification and implantation of PanOptix. Visual quality and patients satisfactory will be assessed three months after the surgery.

Inclusion Criteria:

• age-related cataract patients

  • Eye axis length ≤22.5mm and refraction ≥ +0.5D
  • Predicted postoperative corneal astigmatism ≤0.75D
  • mesopic pupil size between 3.0mm to 5.5 mm
  • Preoperative angle kappa ≤ 0.5 mm
  • Preoperative corneal spherical aberration <0.5μm, high order aberration <0.5μm

Exclusion Criteria:

• In the presence of other ocular diseases that may affect the stability of the lens capsule (pseudoexfoliation syndrome, glaucoma, traumatic cataract, Marfan syndrome, etc.)
• Pupil abnormality (non-reactive pupil, tonic pupils, abnormally shaped pupils, etc.)
• History of any clinically significant retinal pathology or ocular diagnosis (e.g. diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment, optic neuropathy optic nerve atrophy, amblyopia, strabismus, microphthalmos, aniridia, epiretinal membrane etc.) in the study eyes that could alter or limit final postoperative visual prognosis
• Patients with history of ocular trauma or prior ocular surgery including refractive procedures
• Preoperative visual acuity of worse than 0.2 logMAR in any eye.

Hyperopic cataract patients receiving bilateral uneventful phacoemulsification and implantation of PanOptix.